EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
EXELIXIS, INC.
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $16.28B
- P/E (TTM)
- 19.7
- Dividend yield
- –
EXELIXIS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product revenues | $3.01B | $2.52B | $2.27B | $1.95B | $1.45B | $962.59M | $957.62M | $738.53M | $402.57M | $151.50M | 129.8% | +19.6% |
| Net product revenues | $2.12B | $1.81B | $1.63B | $1.40B | $1.08B | $741.55M | $759.95M | $619.28M | $349.01M | $135.38M | 91.5% | +17.3% |
| CABOMETYX | $2.11B | $1.80B | $1.61B | $1.38B | $1.05B | $718.69M | $733.42M | $599.95M | $324.00M | $93.48M | 91.1% | +17.5% |
| License revenues | $214.38M | $349.24M | $178.64M | $162.06M | $249.96M | $167.30M | $165.91M | $200.27M | $96.64M | $56.29M | 9.2% | -38.6% |
| Collaboration revenues | $197.32M | $359.31M | $201.33M | $209.82M | $357.71M | $245.99M | $207.83M | $234.55M | $103.47M | $56.08M | 8.5% | -45.1% |
| COMETRIQ | $9.44M | $11.16M | $13.94M | $25.33M | $23.21M | $22.86M | $26.53M | $19.33M | $25.01M | $41.89M | 0.4% | -15.4% |
| Collaboration services revenues | -$17.05M | $10.06M | $22.69M | $47.76M | $107.76M | $78.69M | $41.91M | $34.28M | – | – | -0.7% | -269.5% |
| Discounts and allowances | -$889.00M | -$708.85M | -$643.65M | -$549.93M | -$375.66M | -$221.04M | -$197.67M | -$119.25M | -$53.56M | – | -38.3% | +25.4% |
| Research and development services revenues | – | – | – | – | – | – | – | $39.50M | $8.74M | $0 | – | – |
| Discounts and allowances | – | – | – | – | – | – | – | $119.25M | $53.56M | $16.12M | – | – |
| Other collaboration revenues | – | – | – | – | – | – | – | $2.86M | -$1.91M | -$207.00K | – | – |
| License revenues | – | – | – | – | – | – | $161.30M | $192.19M | $96.64M | – | – | – |
| Research and development service revenues | – | – | – | – | – | – | $49.97M | $39.50M | $8.74M | – | – | – |
| Other collaboration revenues | – | – | – | – | – | – | -$3.44M | $2.86M | -$1.91M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.14B | $1.82B | $1.65B | $1.41B | $1.09B | $752.89M | $770.24M | $632.93M | $367.91M | $140.71M | 92.3% | +17.4% |
| Europe | $154.17M | $318.63M | $144.97M | $168.59M | $302.07M | $151.63M | $152.77M | $182.88M | $69.79M | $35.75M | 6.6% | -51.6% |
| Japan | $25.59M | $27.08M | $39.49M | $28.73M | $43.50M | $83.02M | $44.76M | $38.02M | $14.78M | – | 1.1% | -5.5% |
| Rest of the world | – | – | – | – | – | – | – | $38.02M | $14.78M | $15.00M | – | – |
From the segment and revenue-disaggregation notes of Exelixis's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.